<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02842294</url>
  </required_header>
  <id_info>
    <org_study_id>P/2012/151</org_study_id>
    <nct_id>NCT02842294</nct_id>
  </id_info>
  <brief_title>Cohort Study to Assess Impact of Chemotherapy Plus Bevacizumab on Health Related Quality of Life in First Line Metastatic Colorectal Cancer</brief_title>
  <acronym>COBEQOL</acronym>
  <official_title>Etude de Cohorte évaluant l'Impact de l'Association chimiothérapie et Bevacizumab en 1ère Ligne du Cancer Colorectal métastatique Sur la qualité de Vie Relative Des Patients. Etude COBEQOL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this french multicenter national study is to assess and compare time to
      quality of life score deterioration (targeted dimensions : global health, fatigue and
      emotional functionning of EORTC QLQC30 according to the first line chemotherapy associated
      with bevacizumab in metastatic colorectal patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>time to health related quality of life score deterioration (targeted dimensions of EORTC QLQC30 : global health, fatigue, emotional functioning)</measure>
    <time_frame>1 year</time_frame>
    <description>The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to health related quality of life score deterioration (non targeted dimensions of EORTC QLQC30 and CR 29)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INT PATSAT32</measure>
    <time_frame>1 year</time_frame>
    <description>The EORTC IN-PATSAT32 is a 32-item satisfaction with care questionnaire to measure patients' appraisal of hospital doctors and nurses, as well as aspects of care organisation and services. It addresses technical competence, information provision, interpersonal skills, availability, waiting time, access, comfort and overall care perception</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality-adjusted life years (QALYs) using EQ5D</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment preference</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>irinotecan based chemotherapy</arm_group_label>
    <description>patients having a 1st line doublet chemotherapy including irinotecan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oxaliplatin based chemotherapy</arm_group_label>
    <description>patients having a 1st line doublet chemotherapy including oxaliplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>triplet chemotherapy</arm_group_label>
    <description>patient having a 1st line triplet chemotherapy including oxaliplatin / irinotecan this cohort was added while primary objective was to compare doublet chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <arm_group_label>irinotecan based chemotherapy</arm_group_label>
    <arm_group_label>oxaliplatin based chemotherapy</arm_group_label>
    <arm_group_label>triplet chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        metastatic colorectal cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age&gt; 18years

          -  metastatic colorectal cancer (non resectable)

          -  1st chemotherapy including bevacizuman

        Exclusion Criteria:

          -  treatment contre-indication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franck Bonnetain, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital of Besancon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marion Jacquin, Msc</last_name>
    <phone>0033370632171</phone>
    <email>fbonnetain@chu-besancon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ikram El SaaD, Msc</last_name>
    <phone>0033370632181</phone>
    <email>iessaad@chu-besancon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU Besançon</name>
      <address>
        <city>Besançon</city>
        <state>Franche Comté</state>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ikram es saad, msc</last_name>
      <phone>0370632181</phone>
      <phone_ext>0033</phone_ext>
      <email>iessaad@chu-besancon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.umqvc.org/en/index.html</url>
  </link>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2016</study_first_submitted>
  <study_first_submitted_qc>July 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2016</study_first_posted>
  <last_update_submitted>July 21, 2016</last_update_submitted>
  <last_update_submitted_qc>July 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bevacizumab</keyword>
  <keyword>health related quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

